NKX019, an experimental cell therapy being developed for scleroderma and other autoimmune diseases, has shown an encouraging safety profile in early clinical testing, according to its developer, Nkarta. According to a press release from Nkarta, 40 people with five autoimmune diseases have received NKX019. The company presented the combined safety findings during an oral presentation […]
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.